Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma

Journal of Immunotherapy

Volumn 19, Issue 4, 1996, Pages 278-295

  Albertini, Mark R ^a   Gan, Jacek ^a   Jaeger, Peter ^a   Hank, Jacquelyn A ^a   Storer, Barry ^a   Schell, Kathy ^a   Rivest, Tammy ^a   Surfus, Jean ^a   Reisfeld, Ralph A ^b   Schiller, Joan H ^a   Sondel, Paul M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anti idiotypic antibodies; Antibody; Dependent cellular cytotoxicity; Human antimouse antibodies; Interleukin 2

Indexed keywords

INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOTOXICITY; FEMALE; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTOSIS; MALE; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 9544244883     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199607000-00004     Document Type: Article

References (38)

1. Schlom J. Antibodies in cancer therapy: basic principles of monoclonal antibodies. In: DeVita VT Jr., Heilman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:464-81.
2. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994;12:1497-515.
3. Schlom J. Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1986;46:3225-38.
4. Oldham RK, Foon KA, Morgan AC, et al. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 1984;2:1235-1244.
5. D3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988;6:1636-48.
6. Crowley NJ, Seigler HF. Possibilities of immunotherapy and gene therapy for malignant melanoma. Semin Surg Oncol 1993;9:273-8.
7. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993;94:297-312.
8. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15: 42-52.
9. Shaw DR, Khazaeli MB, LoBuglio AF. Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J Natl Cancer Inst 1988;80:1553-9.
10. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4.
11. Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 1989;125:191-202.
12. Liao SK, Horton L, Flahart RE, et al. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgGl subclass with specificity for human carcinomas. Hum Antibod Hybridomas 1990;1:66-76.
13. Robinson RR, Chartier J Jr, Chang CP, Horwitz AH, Better M. Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. Hum Antibod Hybridomas 1991;2:84-93.
14. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase 1 trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibod Hybridomas 1992;3:19-24.
15. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialo-gangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Am Acad Sci USA 1986;83:7893-7.
16. d2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47:1098-104.
17. Munn DH, Cheung NKV. lnterleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987;47:6600-5.
18. D2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47:1098-104.
19. D2 antibody 14.18. Cancer Res 1989;49:2857-61.
20. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51:144-9.
21. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990;144:1382-6.
22. Hank JA, Albertini MR, Schiller J, Sondel PM. Activation of multiple effector mechanisms to enhance tumor immunotherapy. J Immunother 1993;14:329-35.
23. Hank JA, Robinson RR, Surfus J, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res 1990;50:5234-9.
24. 2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in in vitro. J Immunother 1994;15:29-37.
25. Albertini MR, Sosman JA, Hank JA, et al. The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer 1990;66:2457-64.
26. Cobbold SP, Rebello PR, Davies HP, Friend PJ, Clark MR. A simple method for measuring patient-antiglobulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990;127:19-24.
27. Harlow E, Lane D, eds. Antibodies: a laboratory manual. New York: Cold Spring Harbor Laboratory, 1988:496.
28. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current protocols in immunology, vol 1. New York: John Wiley & Sons, 1994:2.1.16.
29. Suissa S, Schuster JJ. Exact unconditional sample sizes for the 2 x 2 binomial trial. JR Stat Soc 1985;148:317-27 (series A).
30. Papoian R. Non-specific immunoglobulin interactions may lead to false-positive results in assays for human anti-mouse monoclonal antibodies (HAMA). J Immunoassay 1992; 13: 289-96.
31. Courtenay-Luck NS, Epenetos AA, Winearls CG, Ritter MA. Pre-existing human anti-murine immunoglobulin reactivity due to polyclonal rheumatoid factors. Cancer Res 1987;47:4520-5.
32. Meuer SC, Dumann H, Meyer zum Buschenfelde KH, Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient nonresponders to hepatitis B vaccination. Lancet 1989;1:15-8.
33. Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci USA 1989;86:4240-3.
34. Hank JA, Sosman JA, Kohler PC, Bechhofer R, Storer B, Sondel PM. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. J Biol Response Mod 1990;9:5-14.
35. Kedar E, Rezai AR, Giorgi JV, et al. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells. Nat Immun Cell Growth Regul 1988;7:13-30.
36. Rosenthal NS, Hank JA, Kohler PC, et al. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. J Biol Response Mod 1988;7:123-39.
37. Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 1988; 6: 1440-9.
38. Boldt DH, Ellis TM. Biologic effects of interleukin-2 administration on the immune system. In: Atkins B, Mier JW, eds. Therapeutic applications of interleukin-2. New York: Marcel Dekker, 1993:73-91.